Sanofi pulls drug from FDA program after interference

Good morning, healthcare professional.

Political interference at FDA, blockbuster obesity drug launches, and threats to scientific integrity dominate today's healthcare landscape. Sanofi has withdrawn its diabetes drug from a controversial FDA review program after a political appointee interfered with the approval process, while Novo Nordisk's oral Wegovy pill posted a stunning $355 million first quarter.

These developments signal mounting pressure on regulatory independence and intensifying competition in the obesity market. From a $4.1 billion acquisition in rare disease to fraudulent AI-generated citations infiltrating medical journals, today's stories reveal an industry grappling with political headwinds and scientific credibility challenges.

In today's healthcare digest:

• Political appointee interference forces Sanofi to exit FDA review program
• Novo Nordisk's oral Wegovy pill launches with $355M quarter
• Angelini acquires Catalyst Pharmaceuticals for $4.1 billion
• FDA blocks vaccine safety studies as AI citation fraud surges

Political Interference Disrupts FDA Drug Review Process

Sanofi has requested to withdraw its diabetes drug Tzield from the FDA's controversial voucher program after HHS political appointee Marty Makary interfered with the scientific review process. The move highlights growing concerns about political influence undermining FDA independence and the integrity of drug approvals.

Unpacked:

• Makary, an HHS political appointee, directly intervened in the review of Tzield despite lacking formal authority over FDA decisions.
• The CNPV program allows companies to use priority review vouchers for faster approvals of new indications.
• Sanofi's withdrawal raises questions about whether other drugmakers will face similar political pressure on pending applications.

Novo's Oral Wegovy Pill Posts Strong Launch Quarter

Novo Nordisk's oral semaglutide for obesity generated $355 million in its first full quarter on the market, exceeding expectations and prompting the company to raise its full-year guidance. The pill represents the first oral GLP-1 drug approved for weight loss.

Unpacked:

• CEO Lars Fruergaard Jørgensen cited a pricing "sweet spot" that balances accessibility with commercial viability for the oral formulation.
• The oral version addresses patient preference for pills over injections in the rapidly expanding obesity treatment market.
• Strong early uptake suggests Novo can maintain market leadership despite intensifying competition from Eli Lilly and emerging rivals.

Angelini Acquires Catalyst in $4.1B Rare Disease Deal

Italian pharmaceutical company Angelini Pharma will acquire Catalyst Pharmaceuticals for $4.1 billion, gaining a portfolio of rare neurological disease treatments. The transaction represents Angelini's major push into the U.S. market and specialty neurology space.

Unpacked:

• Catalyst's lead product Firdapse treats Lambert-Eaton myasthenic syndrome, a rare neuromuscular disorder affecting muscle strength.
• The acquisition gives Angelini immediate U.S. commercial infrastructure and expertise in rare disease drug development.
• Deal activity in rare disease continues as companies seek orphan drug portfolios with strong pricing power and limited competition.

FDA Blocks Vaccine Studies as AI Citation Fraud Rises

The FDA has blocked publication of COVID-19 and shingles vaccine safety studies, according to reports, while a separate Lancet analysis reveals a steep increase in fraudulent citations attributed to AI hallucinations in medical research papers. Both issues threaten scientific transparency and research integrity.

Unpacked:

• FDA officials prevented researchers from publishing vaccine safety data, raising concerns about transparency during ongoing public health debates.
• AI-generated fake citations are appearing with increasing frequency in peer-reviewed journals, undermining the reliability of scientific literature.
• The convergence of regulatory opacity and AI-enabled fraud creates new challenges for maintaining trust in medical research.

The Shortlist

• Eli Lilly announced an additional $4.5 billion investment in its Indiana manufacturing complex to expand production capacity.

• Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, strengthening its ophthalmology pipeline with glaucoma and diabetic retinopathy treatments.

• Odyssey Therapeutics raised $279 million in its IPO on its second attempt, providing capital for immune disease drug development.

• Sarepta Therapeutics saw shares tumble after its gene therapy Elevidys posted declining sales that missed analyst expectations.

• Alnylam Pharmaceuticals received an FDA warning letter for making misleading efficacy claims about Amvuttra on its website.